PL2491117T3 - Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę - Google Patents

Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę

Info

Publication number
PL2491117T3
PL2491117T3 PL10773996T PL10773996T PL2491117T3 PL 2491117 T3 PL2491117 T3 PL 2491117T3 PL 10773996 T PL10773996 T PL 10773996T PL 10773996 T PL10773996 T PL 10773996T PL 2491117 T3 PL2491117 T3 PL 2491117T3
Authority
PL
Poland
Prior art keywords
reverse genetics
improved reverse
virus rescue
genetics methods
methods
Prior art date
Application number
PL10773996T
Other languages
English (en)
Inventor
Philip Dormitzer
Björn Keiner
Pirada Suphaphiphat
Michael Franti
Peter Mason
Jennifer Uhlendorff
Mikhail Matrosovich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43382472&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2491117(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2491117T3 publication Critical patent/PL2491117T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL10773996T 2009-10-20 2010-10-20 Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę PL2491117T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27948709P 2009-10-20 2009-10-20
PCT/IB2010/054752 WO2011048560A1 (en) 2009-10-20 2010-10-20 Improved reverse genetics methods for virus rescue
EP10773996.3A EP2491117B2 (en) 2009-10-20 2010-10-20 Improved reverse genetics methods for virus rescue

Publications (1)

Publication Number Publication Date
PL2491117T3 true PL2491117T3 (pl) 2014-05-30

Family

ID=43382472

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10773996T PL2491117T3 (pl) 2009-10-20 2010-10-20 Udoskonalone sposoby odzyskiwania wirusa wykorzystujące odwrotną genetykę

Country Status (14)

Country Link
US (2) US8883481B2 (pl)
EP (1) EP2491117B2 (pl)
JP (2) JP5871806B2 (pl)
KR (1) KR20120083480A (pl)
CN (1) CN102741399A (pl)
AU (2) AU2010309404B2 (pl)
CA (1) CA2778332A1 (pl)
EA (1) EA023811B1 (pl)
ES (1) ES2454815T3 (pl)
HK (1) HK1175200A1 (pl)
NZ (1) NZ599479A (pl)
PL (1) PL2491117T3 (pl)
SI (1) SI2491117T1 (pl)
WO (1) WO2011048560A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111334530A (zh) 2013-03-13 2020-06-26 诺华股份有限公司 乙型流感病毒重配
BR112015030582A2 (pt) 2013-06-06 2017-08-29 Novartis Ag Segmento de hemaglutinina da gripe quimérico e de neuraminidase quimérico, proteína de hemaglutinina quimérica, vírus da gripe rearranjado, métodos para preparação de um vírus da gripe rearranjado e para preparação de uma vacina e sistema de expressão
US11707516B2 (en) 2016-09-27 2023-07-25 Osaka University Method for producing artificial recombinant rotavirus
CN110029129A (zh) * 2019-03-06 2019-07-19 华南农业大学 一种表达鸡st3gal 1基因的mdck稳转细胞株的构建方法
CN110042084A (zh) * 2019-04-11 2019-07-23 浙江森卫生物医药发展有限公司 一种活病毒流感疫苗的生产方法以及制剂
CN117625688B (zh) * 2024-01-26 2024-04-30 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） B亚型禽偏肺病毒反向遗传操作***及其应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
WO1999063064A1 (en) † 1998-06-03 1999-12-09 American Cyanamid Company Novel methods for rescue of rna viruses
GB9916794D0 (en) * 1999-07-16 1999-09-22 Isis Innovation In vitro virus reconstitution
AU764368B2 (en) 1999-09-24 2003-08-14 Smithkline Beecham Biologicals (Sa) Intranasal influenza virus vaccine
ATE473272T1 (de) 2000-03-03 2010-07-15 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
WO2001083794A2 (en) * 2000-04-28 2001-11-08 St. Jude Children's Research Hospital Dna transfection system for the generation of infectious influenza virus
KR20090006239A (ko) † 2000-06-23 2009-01-14 와이어쓰 홀딩스 코포레이션 ｃＤＮＡ로 부터 개 홍역 바이러스의 구출
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
US20040071734A1 (en) 2001-02-23 2004-04-15 Nathalie Garcon Novel vaccine
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
DE10144903A1 (de) * 2001-09-12 2003-03-27 Chiron Behring Gmbh & Co Vermehrung von Viren in Zellkultur
CN103540568A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒***
WO2004113517A2 (en) † 2003-06-09 2004-12-29 Wyeth IMPROVED METHOD FOR THE RECOVERY OF NON-SEGMENTED, NEGATIVE-STRANDED RNA VIRUSES FROM cDNA
AU2004308328B2 (en) 2003-12-23 2009-06-04 Medimmune, Llc Multi plasmid system for the production of influenza virus
JP5393978B2 (ja) 2004-04-05 2014-01-22 ゾエティス・ピー・エルエルシー マイクロ流動化された水中油型乳剤及びワクチン組成物
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
ES2526170T3 (es) 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
BRPI0617373B1 (pt) * 2005-10-14 2022-04-05 The Goverment of The United States of America, Representado por, The Secretary of The Department of Health and Human Services, Centers for Disease Control and Prevention Composições e métodos do vírus da raiva
NZ567817A (en) 2005-11-01 2012-01-12 Novartis Vaccines & Diagnostic Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment
WO2007052061A2 (en) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
BRPI0717219B8 (pt) 2006-10-12 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, e, uso de uma composição imunogênica
NZ577405A (en) 2006-12-06 2012-08-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
WO2010046335A1 (en) * 2008-10-21 2010-04-29 Crucell Holland B.V. Production of influenza virus by reverse genetics in per.c6 cells under serum free conditions

Also Published As

Publication number Publication date
US20150166966A1 (en) 2015-06-18
EP2491117B2 (en) 2017-06-28
CA2778332A1 (en) 2011-04-28
JP2016104004A (ja) 2016-06-09
ES2454815T3 (es) 2014-04-11
HK1175200A1 (en) 2013-06-28
AU2010309404A1 (en) 2012-05-17
JP2013507952A (ja) 2013-03-07
EP2491117B1 (en) 2014-01-01
EA023811B1 (ru) 2016-07-29
AU2010309404B2 (en) 2015-07-09
US8883481B2 (en) 2014-11-11
KR20120083480A (ko) 2012-07-25
EA201270577A1 (ru) 2012-12-28
JP5871806B2 (ja) 2016-03-01
WO2011048560A1 (en) 2011-04-28
CN102741399A (zh) 2012-10-17
EP2491117A1 (en) 2012-08-29
US20130034582A1 (en) 2013-02-07
NZ599479A (en) 2013-11-29
AU2015234265A1 (en) 2015-11-05
SI2491117T1 (sl) 2014-03-31

Similar Documents

Publication Publication Date Title
HK1171212A1 (zh) 電梯救援系統
EP2501753A4 (en) NANOPAPIER RESISTANT
GB201103481D0 (en) No details
PL2453989T3 (pl) Maska oddechowa
GB201016096D0 (en) No details
GB201016097D0 (en) No details
ZA201202823B (en) Elevator
EP2499034A4 (en) WHEELCHAIR
HK1152925A1 (en) Elevator
EP2376361A4 (en) LIFT
GB0906764D0 (en) Rescue aid
GB0909645D0 (en) Methods
GB0907350D0 (en) Methods
GB201118811D0 (en) Separation alarm
GB0912685D0 (en) Methods
HK1175200A1 (en) Improved reverse genetics methods for virus rescue
GB0908435D0 (en) Processes
ZA201105022B (en) Fall arrest system
AU330856S (en) Safe
GB0912950D0 (en) Virus
GB2469633B (en) Lifting system
GB0920067D0 (en) Improved handrail
GB0901056D0 (en) Virus
GB0912159D0 (en) Methods
GB2473269B (en) Emergency device-access